Insulet (NASDAQ:PODD) was upgraded by Raymond James Financial from a “market perform” rating to an “outperform” rating in a report released on Monday.
PODD has been the subject of a number of other research reports. Barclays began coverage on shares of Insulet in a research report on Friday, September 15th. They set an “overweight” rating and a $65.00 price objective for the company. Jefferies Group increased their target price on shares of Insulet from $58.00 to $67.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Canaccord Genuity upgraded shares of Insulet from a “hold” rating to a “buy” rating and increased their target price for the stock from $50.00 to $65.00 in a report on Wednesday, November 1st. Zacks Investment Research lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Saturday, November 11th. Finally, UBS Group upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a report on Monday. Eight equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Insulet has a consensus rating of “Buy” and a consensus price target of $61.29.
Insulet (NASDAQ PODD) opened at $68.76 on Monday. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The firm has a market cap of $4,000.00, a P/E ratio of -137.52 and a beta of 1.58. Insulet has a 1 year low of $37.48 and a 1 year high of $72.99.
In other Insulet news, Director James C. Mullen bought 2,500 shares of Insulet stock in a transaction on Monday, November 13th. The shares were bought at an average cost of $67.45 per share, for a total transaction of $168,625.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.60% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of Insulet in the 3rd quarter valued at $1,414,000. California Public Employees Retirement System raised its holdings in shares of Insulet by 9.2% in the 3rd quarter. California Public Employees Retirement System now owns 71,744 shares of the medical instruments supplier’s stock valued at $3,952,000 after purchasing an additional 6,044 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at $3,229,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at $406,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Insulet in the 3rd quarter valued at $33,373,000.
ILLEGAL ACTIVITY NOTICE: “Insulet (PODD) Upgraded at Raymond James Financial” was originally posted by American Market News and is owned by of American Market News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/08/insulet-podd-upgraded-at-raymond-james-financial.html.
About Insulet
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
